Bill Snyder

The study team included, from left, Linh Tran, Ruben Barricade, PhD, Jaren Perez, and Xin Zhen. (photo by Susan Urmy)

Study reveals new genetic disorder that causes susceptibility to opportunistic infections

An international consortium co-led by Vanderbilt’s Rubén Martínez-Barricarte, PhD, has discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including a life-threatening fungal pneumonia. 

The study could suggest ways to promote the transport of phospholipids and cholesterol out of macrophages, immune system cells that play key roles in all stages of atherosclerosis development.

Study points to new ways to prevent, treat heart disease

Vanderbilt researchers have confirmed the existence of an alternative pathway to atherosclerosis, a finding that may lead to new ways to prevent and treat cardiovascular disease.

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

Study may lead to new diabetes, heart disease treatments

Vanderbilt research found that deletion of an autophagy-participating factor named PIK3C3 from the fat cells of mice led to compromised body temperature control, abnormal blood lipid levels, fatty liver and diabetes.

Roden honored for his leadership in precision medicine

Vanderbilt’s Dan Roden, MD, will receive the PMWC 2023 Pioneer Award Jan. 27 during this year’s Precision Medicine World Conference.

From left, Sean Collins, MD, MSc, Wesley Self, MD, MPH, Jessica Collins, program director, Vanderbilt Coordinating Center, and Matt Shotwell, PhD, play key roles in a now-international clinical trial platform that is investigating therapies aimed at reducing complications in patients hospitalized with COVID-19.

VUMC-led COVID-19 clinical trial platform goes international

The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

1 16 17 18 19 20 115